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The AP-1 transcription factor is activated by multiple growth factors that are critical regulators of breast cell proliferation. We previously
demonstrated that AP-1 blockade inhibits breast cancer cell growth in vitro. Yet a specific role of AP-1 in normal mammary gland development
has not been studied. Using a bi-transgenic mouse expressing an inducible AP-1 inhibitor (Tam67), we found that the AP-1 factor regulates
postnatal proliferation of mammary epithelial cells. Mammary epithelial proliferation was significantly reduced after AP-1 blockade in adult,
prepubertal, pubertal, and hormone-stimulated mammary glands. In pubertal mice, mammary cell proliferation was greatly reduced, and the cells
that did proliferate failed to express Tam67. We also observed structural changes such as suppressed branching and budding, reduced gland tree
size, and less fat pad occupancy in developing mammary glands after AP-1 blockade. We further demonstrated that Tam67 suppressed the
expression of AP-1-dependent genes (TIMP-1, vimentin, Fra-1, and fibronectin) and the AP-1-dependent growth regulatory genes (cyclin D1 and
c-myc) in AP-1-blocked mammary glands. We therefore conclude that AP-1 factor is a pivotal regulator of postnatal mammary gland growth and
development.
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Mammary gland development is a multi-stage and complex
process involving hormone-dependent and hormone-indepen-
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receptor; IHC, immunohistochemical staining; MG, mammary gland; NF-κB,
nuclear factor κB; PR, progesterone receptor; PRL, prolactin; PRLR, prolactin
receptor; TEB, terminal end buds.
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doi:10.1016/j.ydbio.2006.03.042development will provide insights into the molecular
mechanisms that control normal mammary epithelial cell
growth and malignant transformation. Mammary epithelial
cell transformation may occur at the level of the mammary
stem cells or possibly more differentiated breast cells (Al-Hajj
et al., 2003; Dontu et al., 2003; Welm et al., 2002, 2003).
Thus, intervention of the growth signals at both early and late
stages may be required to block normal mammary gland
transformation to ultimately prevent breast cancer. In this
study, we have attempted to block these growth signals in the
mammary gland by specific transcription factor inhibition.
The AP-1 factor is an important transcription factor that
regulates multiple cellular functions such as proliferation,
apoptosis, and organ development. As a key component of
many signal transduction pathways, AP-1 is composed of dimers
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2), or other closely related factors such as ATF proteins (Angel
and Karin, 1991). The Jun members homodimerize or hetero-
dimerize with different Fos or ATF members, while Fos
members only heterodimerize with different Jun members.
Differential expression and activation of Jun and Fos members
allow AP-1 complexes to control a wide variety of cellular
functions (Chiu et al., 1989; Jochum et al., 2001; Schutte et al.,
1989; Yoshioka et al., 1995; Young et al., 2003). AP-1 is
critically involved in controlling cellular proliferation (Holt et
al., 1986), differentiation (Szabo et al., 1991), apoptosis (Ham et
al., 1995), oncogene-induced transformation (Brown et al.,
1993, 1994), and cellular invasion (Angel et al., 1987;Mackay et
al., 1992; Matrisian, 1994; McDonnell et al., 1990). Its
component c-Jun is a positive regulator of cellular proliferation
in fibroblasts and in other cells (Behrens et al., 1999; Johnson et
al., 1993; Schreiber et al., 1999; Wisdom et al., 1999). In AP-1
knockout mice, cJun deletion causes embryonic lethality at
E12.5 (Eferl et al., 1999; Hilberg and Wagner, 1992; Hilberg et
al., 1993; Johnson et al., 1993).We have previously shown that a
cJun dominant-negative mutant, Tam67, inhibits the growth of
breast cancer cells induced by peptide growth factors and
estrogen (Liu et al., 2002, 2004; Ludes-Meyers et al., 2001). We
have also demonstrated that many estrogen-induced growth
regulatory genes are critically dependent on AP-1 (DeNardo et
al., 2005).
The role of AP-1 factor in mammary gland development has
not previously been examined. In this study, we hypothesized
that blockade of the AP-1 factor would interfere with
proliferation and growth of normal mammary gland. To test
this hypothesis, we generated a bi-transgenic mouse that
expresses an inducible AP-1 inhibitor, Tam67, in the mammary
gland. This cJun dominant-negative mutant (cJunDN) lacks the
transactivation domain of cJun, yet retains its DNA-binding and
dimerization domains (Brown et al., 1993). We have used the
Tet-On inducible vector to produce mice that have inducible
expression of Tam67 in the mammary glands. Inducible Tam67
expression resulted in in vivo AP-1 blockade which in turn
suppressed proliferation and growth in developing and
hormone-stimulated mammary glands. We found that mammary
cell proliferation was significantly decreased after AP-1
blockade in adult, pubertal, prepubertal, and hormone-stimu-
lated mammary glands. AP-1 blockade also resulted in
morphological alterations in the prepubertal and pubertal
mammary glands with reduced gland size, branching, and
budding. We further demonstrated that Tam67 downregulated
the transcription of AP-1-dependent genes including two critical
cell cycle regulators, cyclin D1 and c-myc in vivo. These studies
show that the AP-1 transcription factor is critical for postnatal
normal mammary gland growth.
Materials and methods
Generation and genotyping of transgenic mice
The experimental FVB strain mouse for breeding and generation of
transgenic mice was purchased from the Center for Comparative Medicine at
Baylor College of Medicine, Houston, TX. The FVB strain MMTV-rtTAmouse was generated in and obtained from Dr. Chodosh's laboratory
(Gunther et al., 2002). All studies involving the mice were regulated under
the protocol approved by Baylor IACUC. The Tam67 transgene, regulated
by a tetracycline-inducible promoter (prepared from the pUHD-Tam67
vector; Ludes-Meyers et al., 2001), was microinjected into FVB/F1 one-cell
embryos at both Baylor College of Medicine Transgenic Mouse Facility and
at NCI-Frederick. The pUHD-Tam67 transgenic mice were backcrossed with
wild type FVB mice to produce heterozygous Tam67-positive (Tam67+/−)
and Tam67-negative mice (Tam67−/−). The heterozygous Tam67-positive
mice were backcrossed with siblings to generate homozygous Tam67
transgenic mice (Tam67+/+). These homozygous Tam67 mice were crossed
with the MMTV-rtTA mouse to produce a heterozygous pUHD-Tam67+/−/
MMTV-rtTA+/− bigenic mouse. Offsprings carrying both the pUHD-Tam67
and MMTV-rtTA transgenes were identified by PCR analysis of tail DNA.
The pUHD-Tam67 primer sequences are: forward primer, 5′ATGGACTA-
CAAGGACGACGA3′, and reverse primer, 5′GCGATTCTCTCCAG-
CTTC3′. MMTV-rtTA PCR reactions were carried out as described
previously (Gunther et al., 2002). PCR products were separated on a 1.5%
agarose gel, and mice found to carry both transgenes were selected for these
studies.
Doxycycline (Dox) treatment
For mice treated with Dox to induce Tam67 transgene, doxycycline hyclate
(Sigma-Aldrich, Cat# D9891, St. Louis, MO, USA) was supplied in drinking
water at a 2 mg/ml concentration. The Dox-containing water was replaced every
3 days.
Estrogen and progesterone stimulation of mammary glands
The method was described to mimic pregnancy (Laidlaw et al., 1995).
Briefly, silastic tubing was prepared by mixing dry estrogen and progesterone
into the cavity of the tubing. Each transplantable tubing was approximately
1 cm long and contained approximately 5 μg of estrogen and 20 mg of
progesterone. After autoclaving, the tubing was emerged in saline for 24 h
before inserting subcutaneously into the back of experimental mice for the
indicated period of time. Alternatively, β-estrodiol 3-benzoate (E2) (Sigma E-
8515), progesterone (Sigma P-0130), and sesame oil (Sigma S-3547) were
purchased from Sigma-Aldrich Co, St. Louis MO. The mixed suspension of
estrogen and progesterone (E + P) contains 10 μg of E2 and 10 mg of
progesterone dissolved in 1 ml of sesame oil. E + P suspension was injected
at 0.1 ml per mouse/day subcutaneously for the indicated days. The two
methods gave similar results.
In vivo BrdU incorporation
Two hours before sacrificing animals, BrdU solution (Amersham,
Piscataway, NJ) was injected IP at a 0.1 ml/10 g of mouse body weight.
BrdU-positive cells were detected by IHC staining using an anti-BrdU
antibody, as described below. BrdU positive cells were counted in 40 fields
(200×), and shown as a percentage of the total mammary epithelial cells
counted.
Mammary gland whole mount analysis
The #4 inguinal mammary glands were harvested and spread onto
slides, fixed with 10% formalin overnight. The glands were placed in 70%
ethanol for 1 h followed by 30 min in ddH2O before staining overnight
with 0.2% carmine. The mammary glands were dehydrated sequentially in
70%, 90%, and 100% ethanol for 30 min each, and cleared in toluene to
dissolve fat in the gland. The slides were maintained in methyl salicylate
for analysis under light microscope. The number of primary and secondary
branches, and ductal ends were counted for the entire gland. For fat pad
occupancy measurement, the fat pad area was divided into 10 equal
sections from the major gland duct to the farmost edge of the fat pad, each
section was assigned a 10% of the total fat pad volume. The mammary
gland tree occupancy was then estimated according to the sections
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plotted.
Immunohistochemical (IHC) analysis
The mammary glands were collected from FVB mice carrying either no
transgene or the following transgenes: Tam67+/−, MMTV-rtTA+/−, and
Tam67+/−/MMTV-rtTA+/−. The samples were fixed in 4% paraformaldehyde
in PBS solution overnight, and then embedded in paraffin. Tissue sections
were then mounted onto slides and processed for hematoxylin and eosin
staining or IHC staining as previously described (Liu et al., 2002). Briefly,
4 μm tissue sections were cut and mounted onto slides. The slides were
deparaffinized, and endogenous peroxidase was blocked in 3% hydrogen
peroxide buffer. The anti-Flag antibody was used as the primary antibody
(1:100, M2, Sigma-Aldrich, St. Louis, MO, USA) followed by a
biotinylated rabbit anti-mouse antibody (1:100). Peroxidase activity was
visualized using Vector DAB or NovaRed Substrate Kit. Other primary
antibodies used include anti-BrdU and anti-cleaved Caspase 3 (1:100, BD
Pharmingen, San Diego, CA, USA). The slides were counterstained with
hematoxylin for 1 min followed by mounting with a coverslip. Staining-
positive cells were counted in 40 fields and data were expressed as a
percentage of total epithelial cells counted. The above specified antibodies
for Flag and BrdU were used to conduct fluorescent study on the
mammary gland sections from bigenic pUHD-Tam67/MMTV-rtTA mice.
The nuclei were stained with DAPI, Tam67 with FITC, and BrdU with
Texas Red fluorescent dye.
Preparation of enriched mammary epithelial cell pellets
The inguinal mammary glands were aseptically removed from the
experimental mice and placed in DMEM:F12 medium with antibiotics.
After removing the lymph nodes, the mammary tissue was minced into pieces
≤1 mm with a sharp scalpel. The minced tissue was then digested in medium
(DMEM:F12 + antibiotics + collagenase 2 mg/ml + hyaluronidase 0.1 mg/ml)
and shaken at 37°C for 3 h at a speed of 125 rpm. The digested tissue was
then pelleted (1000 rpm for 3 min) and the supernatant removed. Pelleted
cells were washed with PBS + 5% FBS four times (Medina and Kittrell,
2000). These enriched mammary epithelial cells were then used for RNA and
protein preparation.
Western blot analysis
Tissue lysates were prepared by incubating the mammary glands or MCF-7
breast cancer cells in lysis buffer. Protein concentrations in these lysates were
measured by BCA analysis. Equal amounts (40 μg) of total cellular protein
extract were electrophoresed on a 10% acrylamide gel and transferred onto a
nitrocellulose membrane (Amersham, Arlington Heights, IL). The primary
antibodies used were anti-Flag M2 (1:2000 dilution, Cat# F1804, Sigma-
Aldrich, St. Louis, MO), anti-β-Actin (1:8000 dilution, Cat# A5441, Sigma-
Aldrich, St. Louis, MO), anti-cyclin D1 (1:1000 dilution, Cat# RM-9101, Lab
Vision, Fremont, CA), anti-c-Myc (1:500 dilution, Cat# SC-40, Santa Cruz
Biotech, Santa Cruz, CA), and anti-TIMP1 (1:400 dilution, Cat# ab 4047,
Abcam, Cambridge, UK). An anti-mouse or anti-rabbit antibody (1:4000
dilution, Amersham, Piscataway, NJ) was used as the secondary antibody. The
Western blotted bands were visualized using the enhanced chemiluminescence
(ECL) procedure (Amersham, Piscataway, NJ, USA).
Preparation of total RNA from mouse mammary tissue
Total RNAwas extracted as described previously (Liu et al., 2004; Yang et
al., 2001). RNA was prepared from enriched epithelial pellets from mouse
mammary glands (individual mouse or pool of inguinal glands from 5–7 mice)
following the protocol provided by Qiagen Inc. RNA from fixed mammary
tissue in paraffin blocks was prepared by first cutting the tissue into 10 μm
sections, and extracting the RNA from 10 sections using a kit from Epicenter,
Inc. RNA samples were analyzed using quantitative RT-PCR as described
below.Quantitative reverse-transcriptase PCR (Q-RT-PCR)
Quantitative real-time reverse transcriptase PCR (Q-RT-PCR) assays of
transcripts were carried out using gene-specific double fluor-labeled probes
in an ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster
City, CA). The PCR reaction mixture consisted of 300 nM each of the
primers, 100 nM probe, 0.025 units/μl of Taq Polymerase, 125 μM each
of dNTPs, 5 mM MgCl2, ROX reference dye, and 1× Taq Polymerase
buffer. Cycling conditions were 94°C for 1 min, followed by 94°C for
12 s and 60°C for 1 min for 40 cycles. All primers and probes were
designed with Primer Express 1.0 software (Applied Biosystems Foster
City, CA). 6-Carboxy fluorescein (FAM) was used as the 5′ fluorescent
reporter while blackhole quencher 1 (BHQ1) was added to the 3′ end as
quencher. Standard curves for the quantification of each transcript and β-
actin were generated using the serially diluted solution of synthetic
templates, and genome equivalent copies were calculated from the
standard curve. For each sample, TaqMan PCR reactions were performed
in triplicate, plus a non-RT control for each gene of interest, and β-actin
to normalize for input cDNA. The ratio between the values obtained
provides relative gene expression levels. Statistical significance was
determined on triplicate samples using a student t test.
Statistical analysis
Statistical significance was obtained using two-sided Student's t test
to compare proliferation, apoptosis, mammary gland developmental
markers, and AP-1 regulated gene expression (QPCR) in animals
treated with or without Dox, using Prism GraphPad 3.0 Software (San
Diego, CA).Results
Generation of a bigenic mouse line that expresses inducible
Tam67 in the mammary glands
We previously used an inducible Tam67 vector stably
transfected into MCF-7 cells to study the role of AP-1 in
controlling the growth of breast cancer cells (Liu et al., 2002,
2004; Ludes-Meyers et al., 2001). Using this system, we
constructed a Tet-On Flag-Tam67 transgene which was
microinjected into pronuclei of fertilized mouse oocytes (Fig.
1A). Founder mice were screened by Southern blot analysis
(data not shown) and PCR analysis using tail DNA samples.
Two independent founder lines were established for breeding
and experimental purposes that were subsequently bred to
homozygousity (pUHD-Flag-Tam67+/+). We then crossed these
mice with our MMTV-rtTA transgenic mouse (Gunther et al.,
2002) to generate bigenic pUHD-Tam67+/− | MMTV-rtTA+/−
mice (Fig. 1B). The MMTV-rtTA transgenic mouse does not
show any mammary-specific phenotype, but breeds, nourishes,
and behaves normally as compared to its FVB strain counter-
parts (Gunther et al., 2002). Upon feeding the mice the inducer
doxycycline (Dox) (which was dissolved in drinking water) for
2 weeks (Fig. 1C), Tam67 was induced in the mammary glands
in adult virgin mice as shown by Western blotting and
immunohistochemistry (IHC) (Figs. 1D–E). No expression
was observed in salivary glands or other tissues as shown in Fig.
1D. An average of 40% of mammary epithelial cells was found
to express induced Flag-Tam67 in 16-week-old adult female
mice fed with Dox (Fig. 1F). No expression of Tam67 was
detected in control mice that did not receive Dox. Using two
Fig. 1. Generation of bigenic pUHD-Tam67/MMTV-rtTA mice and induction of Tam67 in mammary gland. (A) Schematic drawing of the cJun mutant Tam67 in
which it lacked the transactivating domain, while the DNA binding domain and dimerization domain were intact. A Flag tag was added to the N-terminal of the mutant
protein. (B) Bigenic pUHD-Tam67/MMTV-rtTA mice were generated by crossing heterozygous or homozygous pUHD-Tam67 mice with MMTV-rtTA mice.
Offspring were screened by PCR using tail DNA. (C) The adult bigenic mice were fed with regular water or Dox-water for 2 weeks, and then mammary glands were
collected for protein and IHC studies. (D) Total tissue lysates were prepared from mammary and salivary glands, liver, and muscle from bigenic mice in panel C.
Tam67 was detected in mammary glands of Dox-treated mice byWestern blotting using an anti-Flag antibody. (E) Induction of Tam67 in mammary epithelial cells was
confirmed by IHC using anti-Flag antibody. Original magnification 400×. Scale bar: 50 μm. (F) Data from quantifying 5 bigenic mice treated with water or Dox-water.
Error bars represent SEM.
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experiments described below.
AP-1 blockade in vivo does not alter the global and
histological architecture of mammary glands in adult mice
We next examined whether in vivo Tam67 expression
caused morphological and/or histologic alterations in the
mammary glands of adult virgin female mice (16 weeks old).
We found no significant difference in AP-1-blocked or normal
mammary gland whole mounts at different estrous cycle
stages (Fig. 2A). Histologic sections showed no significant
differences (Fig. 2B). In addition, expression of Tam67 did
not affect these mice in feeding, nursing, social, and physical
activities.AP-1 blockade in vivo reduces mammary epithelial cell
proliferation in adult glands
We next determined the effect of in vivo Tam67
expression on cellular proliferation in adult mouse mammary
glands by counting BrdU-incorporated cells in bigenic
animals (Tam67+/− | rtTA+/−) fed with or without Dox. We
found that the percentage of mammary cells positive for
BrdU was reduced from 3.8% in control mice to 1.2% in
mice fed Dox (P = 0.0011, Figs. 2C–D). We also counted
the BrdU-incorporated cells in unigenic animals (either
Tam67+/− | rtTA−/− or Tam67−/− | rtTA+/−) fed with or
without Dox, and found no significant difference when
compared to the control bigenic mice (Tam67+/− | rtTA+/−,
no Dox) (data not shown). We next examined apoptosis in
Fig. 2. Mammary gland architecture and histology were not altered, but mammary cell proliferation was reduced after AP-1 blockade. (A) Representative mammary
gland whole mount (#4 inguinal gland) analysis of adult bigenic Tam67/rtTA mice fed with water or Dox-water (2× magnification). The global morphology of the
mammary glands showed no significant changes in ductal tree and terminal end buds at two estrous cycle stages. (B) Representative H&E staining of mammary gland.
Original magnification 400×. Scale bar: 50 μm. (C) Representative proliferation assay by IHC staining using anti-BrdU anti-body. Original magnification 400×. Scale
bar: 50 μm. (D) Data from 3–5 bigenic mice treated with water or Dox-water. Error bars represent SEM. (E) Representative cleaved caspase 3 staining by IHC.
Original magnification 400×. Scale bar: 50 μm. (F) Data from 3–5 bigenic mice treated with water or Dox-water. Error bars represent SEM.
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594 Q. Shen et al. / Developmental Biology 295 (2006) 589–603these mammary epithelial cells by IHC using antibody
against cleaved caspase 3. There was no significant
difference between Dox-treated and control animals in the
number of cleaved caspase 3-positive cells (Figs. 2E–F).
These data demonstrate that AP-1 blockade suppresses
mammary cell proliferation in adult virgin mice.
AP-1 blockade suppresses hormone-dependent mammary
gland development in pubertal mice
We next examined the effect of in vivo AP-1 blockade on the
developing mammary gland in mice at 4–6 weeks of age. We
started feeding bigenic pUHD-Tam67+/− | MMTV-rtTA+/− mice
with Dox at 4 weeks of age, and stopped at 6 weeks of age (Fig.
3A). The effects of AP-1 blockade by Tam67 were examined at
the organ and cellular levels. We counted total numbers of
primary mammary duct branches and ductal terminal ends,
measured the outgrowth of the ductal trees, and estimated fat
pad occupancy in the entire #4 mammary gland whole mounts
from Tam67-expressing and control animals. AP-1 blockade
significantly suppressed mammary gland development as
shown in whole mounts (Fig. 3B). The mammary glands of
Tam67-expressing mice showed significantly reduced out-
growth of the mammary gland trees (normal AP-1,
5.8 ± 1.3 mm vs. AP-1 blockade, 1.8 ± 1.4 mm, P = 0.0009),
less occupancy of gland tree in fat pads (normal AP-1, 72 ± 4%
vs. AP-1 blockade, 47 ± 5%, P < 0.0001), fewer primary
branches (normal AP-1, 10.33 ± 1.25 vs. AP-1 blockade,
5.67 ± 0.75, P < 0.0001), and fewer ductal ends (normal AP-1,
277 ± 48 vs. AP-1 blockade, 130 ± 10, P < 0.0001), as
compared to control mice (Figs. 3B–C).
AP-1 blockade in vivo reduces proliferation of mammary
epithelial cells and increases apoptosis in pubertal mice
At the cellular level, approximately 34% of mammary
epithelium was positive for Tam67 expression as confirmed
by IHC staining using an anti-Flag antibody (Figs. 3D–E).
Flag-tagged Tam67 was seen in all mammary gland branches,
ducts, and ductal ends in animals fed Dox (Fig. 3D). We then
examined mammary cell proliferation and apoptosis in the
mammary glands. We first counted BrdU-positive cells in all
bigenic animals (Tam67+/− | rtTA+/−) fed with or without Dox.
The percentage of cells positive for BrdU was significantly
reduced in AP-1 blocked mice (5%), as compared to no Dox
control mice (14% BrdU positive cells) (P = 0.0019, Figs. 3F–
G). We also counted the BrdU-incorporated cells in unigenic
animals (either Tam67+/− | rtTA−/− or Tam67−/− | rtTA+/−) fed
with or without Dox and found no significant difference in
these unigenic mice compared to bigenic control mice
(Tam67+/− | rtTA+/−, no Dox) (data not shown).
We then measured apoptosis in the pubertal mammary
epithelial cells by staining for cleaved caspase 3. Apoptosis was
significantly increased from 1% in control mice to 2.5% in mice
expressing Tam67 (P = 0.0039). From these data, we conclude
that in vivo AP-1 blockade by Tam67 suppresses mammary
gland growth in pubertal mice. These significant changes aredue to decreased proliferation and increased apoptosis in the
pubertal mammary glands.
Dissociation of proliferation of mammary epithelial cells and
Tam67 expression
Since in vivo AP-1 blockade results in defective mammary
gland development in pubertal mice, we hypothesized that
Tam67 has a direct influence on the growth of cells expressing
this AP-1 inhibitor. Using multi-color immunofluorescent
staining, we determined whether Tam67 expression and BrdU
incorporation occurred in the same cell. Using mammary gland
sections from 6-week-old bigenic mice fed with Dox, we
stained for Tam67 (anti-Flag antibody), proliferation (BrdU
antibody), or nuclei (DAPI). Shown in Fig. 4A are transverse
sections from two representative bigenic mice with or without
Dox. Terminal buds from control mice show BrdU-positive
cells, while buds from the glands of AP-1 blocked mice show
both Tam67 and BrdU-positive cells. Most cells that express
Tam67 did not stain for BrdU, demonstrating that Tam67-
expressing cells were not proliferating. To quantitate the
number of cells that were positive for either Tam67 or BrdU,
or positive for both, we randomly selected 65 fields from six
AP-1-blocked pubertal mice and counted the number of total
mammary epithelial cells, Tam67-expressing cells, BrdU-
positive cells, and cells positive for both Tam67 and BrdU. In
a total of 11,825 mammary epithelial cells, 3340 cells were
positive for Tam67 (30%), 604 cells positive for BrdU
incorporation (5%), and 12 cells positive for both Tam67 and
BrdU (0.1% of total cells counted, 1.99% of BrdU-positive
cells) (Fig. 4B). Thus, 98.01% of BrdU-positive cells show no
co-localization with Tam67. This represents a highly significant
negative association between BrdU and Tam67 expression
(P < 0.0001, the correlation coefficient is −0.14). We therefore
conclude that Tam67 expression strongly prevents proliferation
of mammary epithelial cells that express this AP-1 inhibitor.
AP-1 blockade in vivo suppresses mammary gland
development in prepubertal mice
We also examined the effect of in vivo AP-1 blockade on
prepubertal mammary glands in 4-week-old mice. To induce
Tam67 expression in neonatal mice, we treated the mother
(heterozygous Tam67 or rtTA mice) with Dox-water on the day
of delivery, and continued for 4 weeks while the pups drank
milk from their mother and Dox-water (Fig. 5A). We
observed expression of Tam67 in the mammary glands of
the neonatal mice by IHC with anti-Flag staining (Fig. 5B),
indicating the presence of Dox in the milk from the mother.
At 4 weeks of age, the mammary glands from mice
expressing Tam67 show a globally smaller ductal tree,
fewer primary branches and ductal ends, compared to the
other seven groups of control animals that have one or no
transgene (Tam67+/− | rtTA−/−, Tam67−/− | rtTA+/−, or wild
type FVB pups) (P < 0.0001, compared to all control groups,
Figs. 5C–E). From these data, we conclude that AP-1
blockade suppresses the development of mammary glands at
Fig. 3. AP-1 blockade suppresses mammary gland development in pubertal bigenic mice by decreasing proliferation and increasing apoptosis. (A) Bigenic Tam67/rtTA
mice were fed with water or Dox-water at 4 weeks old for 2 weeks, then mammary glands were collected. (B) Representative mammary gland whole mount (#4
inguinal gland) analysis of pubertal bigenic Tam67/rtTA mice fed with water or Dox-water (4× magnification of whole mounts before treatment, 2× magnification of
whole mounts after treatment). Left panel: the ductal tree was less developed globally and locally (see inserts) in Tam67-expressed mammary glands. Right panel:
control group of mice with only rtTA transgene. (C) Data from 6 bigenic mice treated with water or Dox-water. Total number of primary branches, outgrowth past the
lymph node, fat pad occupancy, and total number of ductal ends are plotted. Error bars represent SEM. (D) Representative IHC for the induction of Tam67 (left panel,
original magnification 200×, scale bar: 50 μm), proliferation (middle panel, original magnification 200×, scale bar: 50 μm), and apoptosis (right panel, original
magnification 400×, scale bar: 50 μm), analyzed by IHC using antibodies against Flag, BrdU, and cleaved caspase 3, respectively. (E) Data from 6 bigenic mice treated
with water or Dox-water. Error bars represent SEM.
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Fig. 4. Proliferating mammary epithelial cells rarely express Tam67. (A) Bigenic Tam67/rtTA mice were fed with water or Dox-water at 4 weeks old for 2 weeks, then
mammary glands were collected. Mammary gland sections from paraffin block were stained with anti-Flag and BrdU antibodies. Tam67 expression was labeled with
FITC and BrdU was labeled with Texas Red. Representative images are shown for comparing control and Tam67-expressed mammary gland. Original magnification
400×, scale bar: 10 μm. (B and C) A total of 65 fields (from 6 mice) that had Tam67-expressing cells and BrdU-positive cells were counted. Data from 6 bigenic mice
treated with Dox-water are presented as bar graph.
596 Q. Shen et al. / Developmental Biology 295 (2006) 589–603the neonatal–prepubertal stage, which is typically considered
“hormone-independent” (Hennighausen and Robinson, 1998,
2001).
AP-1 blockade inhibits estrogen + progesterone (E + P)
stimulated mammary gland development
Since the proliferation and growth of the mammary gland in
early and mid-pregnancy can be mimicked by estrogen and
progesterone stimulation, we examined the effect of AP-1
blockade on E + P-stimulated mammary gland growth. Silastic
tubing containing E + P powder was implanted into the back of
adult 13-week-old female mice for 9 days. Dox was then given
for 1 week (starting 2 days after E + P implantation). The
mammary glands were then harvested at day 9 after E + P
treatment, and examined by whole mount processing and IHCstaining (Figs. 6A–B). AP-1 blockade caused decreased
branching and fewer terminal ends (Fig. 6B, whole mounts
and inserts). Induced Tam67 expression was verified with anti-
Flag staining by IHC (Fig. 6B). Approximate 65% of mammary
epithelial cells expressed Tam67 upon Dox treatment (Fig. 6C).
Proliferation was increased after E + P stimulation in both AP-
1-blocked and normal AP-1 (AP-1 not blocked) mammary
glands, as compared with the mammary glands without E + P
stimulation (Fig. 2D). However, there were fewer BrdU-
positive cells in Tam67-expressing mammary glands (9%)
than in E + P stimulated glands (18%, P = 0.007, Figs. 6B, D).
This is the first in vivo evidence that AP-1 blockade suppresses
estrogen and progesterone-induced proliferation of mammary
epithelial cells. AP-1 blockade also resulted in a significantly
increased apoptosis, as measured by cleaved caspase 3 staining
(P = 0.004, Figs. 6B, E).
Fig. 5. AP-1 blockade suppresses mammary gland development in prepubertal bigenic mice. (A) After birth, the bigenic Tam67/rtTA mice were fed with milk from
their mother that drank Dox-water for 4 weeks. The mammary glands were collected from the prepubertal mice at 4 weeks of age. (B) Representative IHC staining for
the induction of Tam67 confirmed in the mammary glands of prepubertal female mice. Original magnification 200×, scale bar: 50 μm. (C) Representative mammary
gland whole mount (#4 inguinal gland) of prepubertal bigenic Tam67/rtTA mice (4× magnification). Left upper panel: the ductal tree was less developed in
Tam67-expressed mammary gland. Right upper panel: control group of mice with only rtTA transgene. Left lower panel: control group of mice with only Tam67
transgene. Right lower panel: control wild-type FVB mice with no transgene. (D) Data from quantifying mammary glands of the transgenic mice in panel C.
Total numbers of primary branches and ductal ends are plotted. The number within each bar represents the total mice in each group. Error bars represent SEM.
*** Indicates P < 0.0001.
597Q. Shen et al. / Developmental Biology 295 (2006) 589–603
Fig. 6. AP-1 blockade inhibits E + P-stimulated mammary gland development in adult bigenic mice. (A) Adult female bigenic Tam67/rtTA mice were given E + P
stimulation at day 0, and then fed with water or Dox-water from day 2 for 1 week. The mammary glands were collected at day 9 from these mice. (B) Representative
mammary gland whole mount (#4 inguinal gland, 2× magnification) and paraffin block sections are shown. IHC staining for Tam67, BrdU, and cleaved caspase 3 was
aligned for comparing the control and Tam67-expressed mammary glands. Original magnification 400×, scale bar: 50 μm. (C–E) Data from 3 transgenic mice in panel
B. Percent of cells positive for Flag, BrdU, and cleaved caspase 3 are plotted. Error bars represent SEM.
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We continued to explore the underlying molecular mechan-
isms by which in vivo AP-1 blockade suppresses mammary
gland development and epithelial cell proliferation. We first
examined the expression of AP-1-regulated genes and then cell
cycle regulators in mammary glands from mice expressing
Tam67. Each RNA sample was prepared from mammary
epithelial cells isolated from inguinal mammary glands from
five to seven mice fed with or without Dox. Three independent
sets of RNA samples (each from 5–7 mice) were used to
measure gene expression. This method had the advantage that
the mRNAwill reliably reflect the expression of AP-1-regulated
genes in mammary epithelial cells. Quantitative RT-PCR was
performed to measure the expression of several AP-1-regulated
genes: TIMP1, vimentin, Fra-1, and fibronectin. We found thatthe mRNA levels of these genes were significantly reduced in
AP-1-blocked mice that were stimulated with E + P (Fig. 7A)
and a similar downregulation was observed in pubertal
mammary epithelial cells from mice treated with Dox (data
not shown). These data demonstrated that Tam67 did cause in
vivo AP-1 blockade.
We have previously shown that the expression of estrogen-
regulated genes is critically dependent on crosstalk between the
AP-1 transcription factor and ER (DeNardo et al., 2005). ER/
AP-1-regulated genes that are important regulators of growth
include cyclin D1 and c-myc. We therefore measured the
expression of these genes in the mammary epithelial cells from
mice treated with or without Dox. Using quantitative RT-PCR,
we found that both cyclin D1 and c-myc transcript levels were
reduced in mammary epithelial cells that were collected from
mice treated with E + P and Dox (Fig. 7A). We also found that
this suppression of cyclin D1 and c-myc occurred in pubertal
Fig. 7. AP-1 blockade downregulates AP-1-regulated genes and cell cycle regulators. (A) Total RNA samples from control and Tam67-expressing mice that were
treated with E + P were used as templates for quantitative real-time PCR analysis. The mRNA levels of Timp1, vimentin, Fra-1, fibronectin, cyclin D1, and c-myc (all
AP-1-regulated genes) were plotted. Error bars represent SEM. (B) Protein levels of cyclin D1, c-Myc, and TIMP1 were detected by Western blotting. β-Actin was
shown as an internal loading control. Anti-flag antibody was used for confirmation of Tam67 induction upon Dox treatment.
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TIMP1 were also studied using Western blotting (Fig. 7B).
These results demonstrate that the AP-1 inhibitor Tam67
suppresses AP-1-regulated genes and cell cycle regulators
cyclin D1 and c-myc in vivo, which, in turn, suppress the growth
of the mammary gland at different postnatal developmental
stages.
Discussion
The AP-1 factor is an important transcription factor that
regulates multiple cellular functions such as proliferation,
apoptosis, and development. In order to investigate the in
vivo role of the AP-1 transcription factor in normal mammary
gland development, we generated a unique bigenic transgenic
mouse that expresses an inducible AP-1 inhibitor, Tam67, in the
mammary gland. Our data demonstrate that AP-1 blockadesuppresses mammary gland development in prepubertal,
pubertal, adult, and hormone-stimulated mice. Furthermore,
AP-1 blockade suppresses mammary cell proliferation and
inhibits AP-1-regulated gene expression in mammary epithelial
cells. We speculate that this suppression of proliferation is
caused by suppression of critical growth regulatory genes such
as cyclin D1 and c-myc. These studies demonstrate that the AP-
1 transcription factor is critical for mammary gland develop-
ment. Our results demonstrate that in vivo AP-1 blockade
causes suppression of mammary gland development at multiple
stages. This is the first evidence that the AP-1 factor has an
important role in early and pubertal mammary gland develop-
ment, and in hormone-stimulated adult mammary gland
development.
Mammary gland development is divided into distinct stages
including embryo, prepuberty, puberty, pregnancy, lactation,
and involution stages. Known molecules that regulate
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receptor (PRLR), Stat5a, ER, PR, C/EBP, cyclin D1, and others
(Hennighausen and Robinson, 1998). After birth and before
puberty (up to weaning, 3–4 weeks of age), the mammary
glands continue to grow from embryonic stage without the
influence of endocrine hormones, though stromal EGFR and
ERα are required (Bocchinfuso et al., 2000; Wiesen et al.,
1999). During pubertal development of mammary glands, the
ovarian hormones, estrogen and progesterone, stimulate ductal
growth. Terminal end buds lead to the development of
secondary and tertiary duct structures by elongation andFig. 8. Schematic model of the mechanism by which AP-1 reglumen formation (Humphreys et al., 1996; Imagawa et al.,
2002). These hormones, along with ERα and its downstream
effector IGF-Is and IGF-IR, PR-B, glucocortocoid receptor, and
other factors, modulate the proliferation, apoptosis, and
organogenesis of the developing mammary gland (Bonnette
and Hadsell, 2001; Kleinberg et al., 2000; Mueller et al., 2002;
Mulac-Jericevic et al., 2000). During pregnancy, PRL and its
receptor, and placental lactogens are the key hormones
modulating mammary alveolar and lobular development
(Brisken et al., 1999; Ormandy et al., 1997). In addition, the
Stat5 signaling pathway, transcription factor C/EBP, cyclin D1,ulates mammary cell proliferation and gland development.
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accompanying proliferation and apoptosis (Hennighausen and
Robinson, 1998; 2001; Seagroves et al., 2000; Sicinski et al.,
1995). ER is critical for the development of adult mammary
glands as well as embryonic mammary glands as shown by
Korach's group using ERα knockout mice (Bocchinfuso et al.,
2000; Korach et al., 1996). Peptide hormones (such as FGF and
PTHR/PTHrP), hormone receptors (such as FGFR, EGFR, and
ER in the stroma), and other oncogenes (such as Wnt) are also
involved in the early development of mammary gland
(Bocchinfuso et al., 2000; Dunbar et al., 1999; Foley et al.,
2001; Mailleux et al., 2002; Veltmaat et al., 2004; Wiesen et al.,
1999; Wysolmerski et al., 1998, 2001). These growth factors
and hormones activate signal transduction pathways that
ultimately activate transcription factors such as AP-1 to regulate
gene expression.
A role of AP-1 in postnatal mammary gland development
has not previously been found. The AP-1 factors may regulate
AP-1-dependent gene expression by several mechanisms (as
shown in Fig. 8). Estrogen stimulates gene expression by
activating transcription factors such as ER or AP-1 directly or
indirectly (shown in the top half of Fig. 8). Activation of these
transcription factors induces gene expression which then
regulates mammary gland development. The AP-1 complex
(shown as dimers of Jun and Fos proteins) and ER may interact
at AP-1 binding sites or estrogen response elements (EREs) to
regulate specific AP-1-dependent and ER-dependent genes that
regulate genes with either AP-1 binding sites or EREs within
their promoters (as shown in the top half of Fig. 8). It is well
documented that cyclin D1, Stat5a, PR, PRLR, and others are
estrogen-induced genes that are required for postnatal mamma-
ry gland development. We recently found that the AP-1 factor
directly and indirectly regulates cyclin D1 expression through
AP-1 and E2F response elements within this promoter
(unpublished observation). AP-1 binding sites have also been
identified in the Stat5a promoter (Crispi et al., 2004) and in the
prolactin gene promoter (Caccavelli et al., 1998; Farrow et al.,
2004; Manfroid et al., 2001, 2005; Van De Weerdt et al., 2000).
Jun and Fos proteins also regulate PR expression via an AP-1
binding site (Petz et al., 2004). In addition, AP-1 may regulate
cyclin D1, PR, and PRL expression through AP-1/ER crosstalk
(DeNardo et al., 2005; Petz et al., 2002). Our results
demonstrate that AP-1 blockade by Tam67 inhibits the
expression of cell cycle regulators such as cyclin D1 and
cMyc to suppress postnatal mammary gland development.
Taking these together, we speculate that AP-1 may also regulate
Stat5a, PRL, PRLR and possibly other growth regulatory
proteins. The role of AP-1 in regulating the expression of these
proteins in postnatal mammary glands is now under
investigation.
The results presented here show that AP-1 blockade leads to
reduced mammary epithelial cell proliferation with a slight
increase in apoptosis. Using the MMTV-driven inducible
system, Tam67 expression and the resulting AP-1 blockade
occurred only in normal mammary epithelial cells. However, in
our previous studies, AP-1 blockade induced by Tam67 can
inhibit proliferation of normal mammary epithelial cells, andsome, but not all breast cancer cell lines grown in vitro (Liu et
al., 2002; Ludes-Meyers et al., 2001). Other studies have shown
that Tam67 expression in mouse keratinocytes did not affect
proliferation of these skin cells (Young et al., 1999, 2003). The
differential effect of Tam67 in the mammary gland as compared
to keratinocytes suggests that mammary epithelial cells are
more dependent on AP-1 for their growth than are
keratinocytes.
Tam67 has previously been shown to form an inactive
complex with its dimerizing partners that will occupy the AP-1
binding site and suppress target gene expression (Brown et al.,
1994). Here we show that a set of AP-1-regulated genes such as
TIMP1, vimentin, fibronectin, Fra-1, cyclin D1 and c-myc were
downregulated in mouse mammary glands after AP-1 blockade.
The growth suppressive effects of AP-1 blockade are likely due
to downregulation of cyclin D1 and c-Myc, and perhaps other
regulatory proteins. Our finding that in vivo AP-1 blockade
suppresses cyclin D1 and c-Myc expression in the mouse
mammary glands strongly supports our conclusion that AP-1
factor regulates postnatal mammary epithelial proliferation and
mammary gland development. These data raise the intriguing
possibility that AP-1 transcription factor may also be required
for mammary gland transformation, making this transcription
factor a promising target for future drugs for the treatment or
prevention of human breast cancer.
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